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In Brief Tarangelo et al. show that stabilization of wild-type p53, leading to expression of the downstream target CDKN1A (encoding p21 CIP1/WAF1 ), delays the onset of ferroptosis in response to subsequent cystine deprivation in human and in mouse cancer cells.
INTRODUCTION
The p53 tumor suppressor is mutated or functionally inactivated in many tumors (Bieging et al., 2014; Pfister and Prives, 2017) . How wild-type p53 suppresses tumor formation remains unclear despite decades of study. Recently, acetylation-defective p53 mutants were shown to promote ferroptosis, an iron-dependent, oxidative and non-apoptotic form of cell death (Jiang et al., 2015; Wang et al., 2016) . These p53 mutants are unable to induce apoptosis, cell-cycle arrest, or senescence, yet retain the ability to prevent tumor formation in mice (Li et al., 2012) , suggesting that p53-induced ferroptosis could be responsible for tumor suppression. However, other results suggest that p53 expression may inhibit ferroptosis in certain cells, either through a posttranslational mechanism (Xie et al., 2017) or via effects on the transcription of metabolic genes (Jennis et al., 2016) . Thus, the impact of p53 expression on ferroptosis sensitivity is poorly understood.
System x c
À is a cystine/glutamate antiporter whose constitutive activity suppresses ferroptosis in many cell types (Dixon et al., 2012; Stockwell et al., 2017) . System x c À -mediated cystine import is necessary for the synthesis of the antioxidant tripeptide (reduced) glutathione (GSH). Depletion of cystine and/or GSH results in the iron-dependent accumulation of lethal lipid-reactive oxygen species (ROS), a process that is suppressed by lipophilic antioxidants such as ferrostatin-1 (Dixon et al., 2012; Stockwell et al., 2017) . Here, we examined the relationship between wild-type p53 expression and ferroptosis sensitivity in response to system x c À inhibition. We find that wild-type p53 stabilization can decrease system x c À activity yet simultaneously reduce ferroptosis sensitivity in a broad range of cell types. This protective effect requires expression of the p53 transcriptional target CDKN1A (encoding p21) and conservation of intracellular GSH. These results indicate that the p53-p21 transcriptional axis negatively regulates ferroptosis in cancer cells.
RESULTS p53 Stabilization Suppresses Ferroptosis in Response to System x c À Inhibition
Human HT-1080 fibrosarcoma cells are a classic ferroptosis model that express wild-type p53 (Dixon et al., 2012; Stockwell et al., 2017; Tarunina and Jenkins, 1993) . To characterize the effects of p53 expression on ferroptosis in these cells, we used CRISPR/Cas9 technology to isolate a clonal TP53 knockout (TP53 KO ) cell line. The small-molecule MDM2 inhibitor nutlin-3 (10 mM, 48 hr) increased p53 levels, upregulated the canonical p53 target genes CDKN1A and MDM2, and induced G1 cellcycle arrest in parental (control) cells, but not in TP53 KO (Dixon et al., 2014 ) ( Figure 1D ). Cell death was quantified during this second phase using scalable time-lapse analysis of cell death kinetics (STACK), an imaging-based method that measures cell death within a population over time (Forcina et al., 2017) . We observed that control cells pretreated with nutlin-3
were less sensitive to erastin2-induced cell death, both across erastin2 concentrations and over time (Figures 1E and 1F) . By contrast, TP53 KO cells were equally sensitive to erastin2 regardless of nutlin-3 pretreatment ( Figures 1E and 1F) . The protective effect of nutlin-3 pretreatment on subsequent erastin2-induced cell death could also be detected in HT-1080 cells using an alternative measure of cell viability, the metabolic indicator PrestoBlue ( Figure S1A ).
We next tested the generalizability of the findings obtained in HT-1080 cells to other cell types. Similar to HT-1080 cells, nutlin-3 pretreatment increased the expression of canonical p53 target genes and transiently suppressed erastin2-induced Data represent mean ± SD from at least three independent biological replicates (B, C, E-G, and I).
, primary mouse embryonic fibroblasts (Figures S1B and S1C). Nutlin-3 pretreatment also increased p53 protein levels in p53 wild-type U-2 OS, ACHN, Caki-1, and A549 cells without causing substantial cell death alone, and delayed the onset of erastin2-induced ferroptosis ( Figures S1D-S1F ). SJSA-1 cells express wild-type p53 and are susceptible to nutlin-3-induced apoptosis (Vassilev et al., 2004) . In these cells, a 24 hr nutlin-3 pretreatment elevated p53 levels and suppressed erastin2-induced cell death to the level of cell death observed with nutlin-3 alone, indicating that p53 stabilization may be capable of inducing apoptosis and suppressing ferroptosis simultaneously ( Figures S2A-S2C ). Nutlin-3 pretreatment had weaker effects on erastin2-induced ferroptosis in p53 null H1299 cells and p53 mutant T98G cells, consistent with a requirement for wild-type p53 expression and stabilization for suppression of erastin2-induced ferroptosis in cancer cells (Figures S1D-S1F). However, in noncancerous IMR-90 human fetal lung fibroblasts that express wild-type p53, nutlin-3 pretreatment elevated p53 levels without altering the onset of erastin2-induced ferroptosis, indicating that the association of p53 stabilization with protection against ferroptosis is not universal (Figures S2D and S2E) .
While erastin2 inhibits system x c À function (Dixon et al., 2014) , it could potentially have other effects on the cell. To address this point, HT-1080 control and TP53 KO cells were pretreated with nutlin-3 or DMSO then directly cultured in medium lacking cystine. Under these conditions, nutlin-3 pretreatment suppressed the death of control cells, but not TP53 KO cells (Figures 1G and 1H ; note that nutlin-3 treatment alone was not lethal to either cell line). Cell death in response to cystine deprivation was completely blocked by a potent and specific antioxidant inhibitor of ferroptosis, ferrostatin-1 (Fer-1, 2 mM) (Dixon et al., 2012) ( Figure 1G ). Erastin2-induced death was likewise completely suppressed by co-treatment with a structurally distinct nitroxide-based free radical scavenger ( Figure S2F ), indicating that nutlin-3 pretreatment does not alter the mode of cell death caused by cystine deprivation or erastin2 treatment.
Using the cystine deprivation paradigm, we examined the ability of p53 stabilization to promote long-term cell survival. We pretreated HT-1080 control and TP53 KO cells with DMSO or nutlin-3, then deprived cells of cystine for 72 hr in the continued presence of DMSO or nutlin-3, at which point cystine was restored (without DMSO or nutlin-3) and cell viability examined over the following 96 hr. Nutlin-3 pretreatment delayed the onset of cell death over the 72-hr cystine deprivation period in control versus TP53 KO cells, as expected ( Figure 1I ). Moreover, upon cystine restoration, only nutlin-3-pretreated control cells exhibited a steady decrease in the lethal fraction over time, which is best explained by an increase in the number of live cells within the population (Forcina et al., 2017) (Figure 1I , orange datapoints). Collectively, these results suggest that p53 stabilization promotes cell survival in response to cystine deprivation by blocking ferroptosis.
Delayed Ferroptosis Onset Requires p21 p53 may impact ferroptosis via transcriptional or posttranslational mechanisms (Jennis et al., 2016; Jiang et al., 2015; Xie et al., 2017) . In HT-1080 cells, more than 12 hr of nutlin-3 pretreatment were required to delay the onset of erastin2-induced ferroptosis, which suggested a p53-dependent transcriptional effect ( Figure S3A) 26 (KP 25,26 ) mice (Johnson et al., 2001 (Johnson et al., , 2005 . KP WT and KP 25, 26 cells express oncogenic Kras
G12D
. When infected with a virus directing the expression of Cre recombinase (Ad-Cre), but not a control adenovirus (Ad-empty), these cells re-expressed wildtype p53, upregulated the p53 target genes Mdm2 and Cdkn1a, and exhibited reduced sensitivity to erastin2-induced, Fer-1-sensitive cell death (Figures 2A, 2B CDKN1A (encoding p21) is a key transcriptional target of p53 that can inhibit cell-cycle progression and impact glutathione metabolism, making it a logical candidate to examine in the context of ferroptosis (Abbas and Dutta, 2009; Maddocks et al., 2013) . Nutlin-3 treatment resulted in upregulation of CDKN1A mRNA and p21 protein in control but not TP53 KO HT-1080 cells, consistent with a possible role in ferroptosis regulation ( Figures 1B and 2D ). We therefore used CRISPR to generate two independent clonal HT-1080 CDKN1A KO cell lines that lacked p21 expression and failed to undergo nutlin-3-induced cell-cycle arrest despite normal stabilization of p53 and upregulation of the p53 target gene MDM2 ( Figures 2D-2F ). Strikingly, and in contrast to control cells, nutlin-3 pretreatment conferred essentially no protection against erastin2-induced cell death in CDKN1A KO1/2 cells, either across compound doses or over time (Figures 2G and 2H) . Short hairpin RNA (shRNA)-mediated silencing of CDKN1A in Caki-1 cells likewise abrogated the ability of nutlin-3 pretreatment to delay subsequent erastin2-induced cell death ( Figures S3F and S3G) . These results suggest a requirement for p21, downstream of p53, to suppress ferroptosis in response to system x c À inhibition.
p21 causes cell-cycle arrest by inhibiting the activity of cyclindependent kinase (CDK) complexes that contain the G 1 /S kinases CDK2, CDK4 and CDK6 (Abbas and Dutta, 2009) . We investigated whether cell-cycle arrest was sufficient to protect against ferroptosis. Lentiviral overexpression of CDKN1A in HT-1080 cells delayed the onset of erastin2-induced ferroptosis relative to cells transduced with an empty control virus ( Figures  S3H and S3I) . To test whether cell-cycle arrest per se was sufficient to suppress ferroptosis, we inhibited cell-cycle progression downstream of p21 at the level of CDK4/6. Inhibition of CDK4/6 function using the specific inhibitor palbociclib (2 mM, 48 hr) arrested the proliferation of both control and TP53 KO HT-1080 cells, predominantly in G1 ( Figures 2I and 2J ). However, pretreatment with palbociclib did not alter the sensitivity of either control or TP53 KO cells to erastin2-induced ferroptosis ( Figure 2J ). Thus, cell-cycle arrest caused by CDK4/6 inhibition does not appear to be sufficient to inhibit ferroptosis.
p53 Stabilization Can Decrease System x c À Activity
Ferroptosis is inhibited by system x c À activity (Stockwell et al., 2017) , and acetylation-defective p53 mutants sensitize to ferroptosis by repressing SLC7A11/xCT expression and system x c À function (Jiang et al., 2015) . Indeed, direct small interfering RNA (siRNA)-mediated silencing of SLC7A11 expression sensitized HT-1080 cells to erastin2-induced cell death ( Figures 3A  and 3B ). We therefore examined how stabilization of wild-type p53, which protects from cell death (e.g., Figures 1 and 2) , altered xCT/SLC7A11 expression and system x c À function. In HT-1080 control cells basal system x c À activity (i.e., Na + -independent glutamate release [Dixon et al., 2014] ), xCT protein levels and SLC7A11 mRNA expression were all reduced by nutlin-3 treatment (Figures 3C-3E) . System x c À activity and SLC7A11/xCT expression were lower in TP53 KO cells and insensitive to nutlin-3 ( Figures 3C-3E ). These effects may be due to reorganization of metabolic networks in mutant cells to compensate for the loss of p53. In both cell lines, system x c À activity was fully inhibited by treatment with erastin2 (1 mM, 2 hr), confirming the specificity of this assay ( Figure 3C) . A known inducer of xCT expression, tert-butylhydroquinone (tBHQ, 100 mM, 48 hr [Lewerenz et al., 2012] ) increased xCT/ SLC7A11 levels, validating our reagents ( Figures 3D and 3E ). We reasoned that the inhibitory effect of p53 stabilization on system x c À function must be counterbalanced by other alterations that ultimately reduce cellular ferroptosis sensitivity. The antioxidant master regulator transcription factor NFE 2-like 2 (NRF2) can be activated by p21 (Chen et al., 2009 ), and we wondered whether p21-stimulated NRF2 activity and antioxidant gene expression could be compromised by disruption of the p53-p21 axis. However, tBHQ, a bona fide inducer of NRF2 activity (Lewerenz et al., 2012) , stimulated the expression of two canonical NRF2 target genes, HMOX1 and GCLM, equally in control, TP53 KO and CDKN1A KO1/2 cells ( Figure 3F ). Conversely, nutlin-3 treatment did not consistently enhance HMOX1 and GCLM expression in these cells ( Figure 3F ). Thus, it appeared unlikely that the p53-p21 axis suppressed ferroptosis by enhancing NRF2 activity.
p53 Stabilization Leads to Conservation of Intracellular Glutathione
The toxic lipid ROS accumulation occurring during ferroptosis can be monitored using the lipid ROS probe C11 BODIPY 581/ 591 (Dixon et al., 2012) . HT-1080 cells pretreated with DMSO and then treated with erastin2 (1 mM, 10 hr) exhibited robust probe oxidation, both on internal membranes and in a distinct ring around the periphery of the cell ( Figure 4A ). Pretreatment with nutlin-3 reduced probe oxidation upon subsequent erastin2 treatment in both locations ( Figure 4A ). Lipid ROS accumulation is opposed by GPX4, a (reduced) glutathione (GSH)-dependent lipid hydroperoxidase (Stockwell et al., 2017) . In control HT-1080 cells, total glutathione levels (as determined using Ellman's reagent) were not elevated by nutlin-3 pretreatment ( Figure 4B) . Notably, however, nutlin-3-pretreated control cells exhibited higher glutathione levels than control cells pretreated with DMSO, or TP53 KO or CDKN1A KO1/2 cells pretreated with DMSO or nutlin-3, following erastin2 treatment (1 mM, 8 hr) (Figures 4B and S4A ).
Based on these results, we investigated whether p53 stabilization delayed ferroptosis by limiting GSH depletion or enhancing GSH synthesis using mass spectrometry and carbon-13 labeling. HT-1080 control and TP53 KO cells were pretreated with either DMSO or nutlin-3 for 48 hr and then incubated in the presence or absence of erastin2 (1 mM) for 8 hr in medium containing uniformly (U) labeled-13 C-serine. Within the cell, serine can be converted into glycine, which is then directly incorporated into GSH via de novo synthesis, yielding GSH M+2 ( Figure 4C ). Serine also can be utilized in the synthesis of cysteine via the transsulfuration pathway, ultimately resulting in GSH M+5 (via glycine and transsulfuration; Figure 4C ). In control and TP53 KO cells, most intracellular serine was labeled (M+3) at 8 hr, and this labeling was not grossly affected by nutlin-3 or erastin2, indicating that these treatments did not affect the uptake of the tracer (Figure S4B) . In control cells, nutlin-3 pretreatment resulted in higher levels of total GSH (all isotopologues) following erastin2 treatment compared to cells pretreated with DMSO, or compared to TP53 KO cells pretreated with DMSO or nutlin-3 ( Figure 4D ).
GSSG represented a minor fraction of the total glutathione in control (< 10%) and TP53 KO (< 20%) cells and was unaffected by nutlin-3 pretreatment, indicating that higher levels of GSH likely account for the increase in total glutathione.
Examining the distribution of GSH isotopologues, we observed that de novo GSH synthesis was inhibited in control cells pretreated with nutlin-3, as indicated by a reduction in GSH M+2 relative to control cells pretreated with DMSO (Figure 4E ). This effect was not observed in TP53 KO cells pretreated with either nutlin-3 or DMSO ( Figure 4E ). In control cells pretreated with nutlin-3, most of the GSH retained upon erastin2 treatment was the unlabeled M+0 species, suggesting that it was derived from preexisting pools rather than de novo (i.e., stress-induced) synthesis. Under no conditions did we observe accumulation of GSH M+5, indicating that the transsulfuration pathway was not active in these cells ( Figure 4E ). Based on these results, we predicted that GSH synthesized during the pretreatment phase (i.e., detected as GSH M+0 in our experiments) was important for the protective effect of p53 stabilization in response to system x c À inhibition. Consistent with this prediction, addition of the GSH biosynthesis inhibitor buthionine sulfoximine (BSO, 100 mM, 24 hr) during the nutlin-3 pretreatment phase, but not the erastin2 treatment phase, sensitized control HT-1080 cells to ferroptosis, regardless of nutlin-3 pretreatment ( Figure 4F ).
DISCUSSION
Depending on the context, p53 can either promote or prevent cell death (Kruiswijk et al., 2015; Paek et al., 2016) . We find that prolonged (>24 hr) stabilization of wild-type p53 renders many cancer cells less sensitive to ferroptosis induced by system x c À inhibition or direct cystine deprivation. This reduced sensitivity to ferroptosis requires p21 and the conservation of intracellular GSH ( Figure S4C ). How activation of the p53-p21 axis reduces cellular reliance on system x c À -mediated cystine import and ongoing de novo GSH synthesis is unclear. p21 inhibits cell-cycle progression (Abbas and Dutta, 2009 ), but experiments using the CDK4/6 inhibitor palbociclib tentatively suggest following pretreatment ± nutlin-3. BD: below limit of detection. (D) p53 and xCT protein levels following DMSO, tert-butylhydroquinone (tBHQ, 100 mM), or nutlin-3 (10 mM) treatment for 48 hr.
(E and F) SLC7A11 (E) and HMOX and GCLM (F) mRNA expression following DMSO (vehicle), nutlin-3 (10 mM), or tBHQ (100 mM) treatment for 48 hr. Data represent mean ± SD from at least three independent biological replicates (B, C, E, and F).
that inhibition of proliferation and cell-cycle arrest per se are insufficient to inhibit ferroptosis. It is possible that p21-dependent inhibition of additional or alternative CDKs (e.g., CDK1/2) is required to conserve GSH and inhibits ferroptosis through induction of a more complete cell-cycle arrest. Alternatively, p21 could potentially enhance GSH retention through effects on CDK-regulated metabolic enzymes (Ewald et al., 2016) . Our results are broadly consistent with the recent findings that ferroptosis is inhibited by basal p53 expression in colorectal cancer cells (Xie et al., 2017) , but suggest a specific role for p53-mediated transcription and upregulation of p21 in the protective response conferred by p53 stabilization. Our results appear to contradict the findings that expression of acetylation-defective p53 mutants (i.e., 3KR) reduce system x c À function and sensitize cancer cells to ferroptosis (Jiang et al., 2015; Wang et al., 2016) . However, acetylation-defective p53 mutants are unable to induce p21 (Jiang et al., 2015) . We speculate that system x c À downregulation and p21 upregulation could be two branches of a coordinated p53-mediated response that normally decreases cystine import to match the lower metabolic demands of growth-arrested cells. One possibility is that such a coordinated response is modulated by acetylation and other p53 post-translational modifications (e.g., phosphorylation) (Jennis et al., 2016) to fine-tune ferroptosis sensitivity in specific contexts. Delaying the onset of ferroptosis by even a few hours could help a cancer cell survive transient exposure to harsh environmental conditions in vivo, such as the oxidizing conditions encountered in the bloodstream during metastasis (Piskounova et al., 2015) . This could help explain why some cancers retain the ability to express wild-type p53 and p21.
Experimental Procedures
Further details and an outline of the resources used in this work can be found in the Supplemental Experimental Procedures.
Cell Lines
For cell viability studies, polyclonal Nuc::mKate2-expressing HT-1080 parental, TP53 KO , CDKN1A KO1/2 , U-2 OS, A549, T98G, H1299, ACHN, and CAKI-1 cell lines were generated by transducing parental cell lines with NucLight Red Lentivirus (Essen Bioscience) followed by selection with puromycin (1-2 mg/mL) for 4 days (Forcina et al., 2017) . Murine lung tumor cell lines were generated by dissection of lung tumors from 11-week-old Kras 26 male mice. Cultures were established in N5 medium supplemented with epidermal growth factor (EGF) (20 ng/mL) and fibroblast growth factor (FGF) (20 ng/mL), sorted by fluorescence-activated cell sorting (FACS) (Stanford Shared FACS facility) for EpCam positivity (BioLegend) and then switched to DMEM Hi-glucose media.
p53
+/+ and p53 À/À mouse embryonic fibroblasts (MEFs) were isolated from E13.5 embryos as previously described (Johnson et al., 2005) and cultured in DMEM Hi-glucose media. All media were supplemented with 10% fetal bovine serum and 13 Pen/Strep (Life Technologies). All cell lines were grown at 37 C with 5% CO 2 in humidified tissue culture incubators (Thermo Scientific). All experiments involving cell isolation from tissues or embryos were performed in accordance with the Stanford APLAC #10382.
Data Analysis
Data were analyzed using Microsoft Excel and GraphPad Prism (v.6.0h) and are represented as mean ± SD or ± 95% confidence interval. Lethal fraction scoring was performed as using Microsoft Excel and GraphPad Prism, as previously described (Forcina et al., 2017) .
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures and four figures and can be found with this article online at https://doi.org/ 10.1016/j.celrep.2017.12.077.
